Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Evolus, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
EOLS
Nasdaq
2834
www.evolus.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Evolus, Inc.
Evolus (EOLS) Surges 28.3%: Is This an Indication of Further Gains?
- Jan 22nd, 2025 12:46 pm
Evolus, An AbbVie And Botox Rival, Just Hit The Stratosphere — Here's Why
- Jan 21st, 2025 9:04 pm
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company’s Guidance
- Jan 21st, 2025 1:00 pm
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Jan 17th, 2025 9:05 pm
Evolus, Inc.'s (NASDAQ:EOLS) Path To Profitability
- Dec 20th, 2024 10:39 am
Here's Why Evolus (EOLS) Could be Great Choice for a Bottom Fisher
- Nov 18th, 2024 2:55 pm
Down -29.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Evolus (EOLS)
- Nov 14th, 2024 2:35 pm
Earnings Update: Evolus, Inc. (NASDAQ:EOLS) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
- Nov 9th, 2024 2:23 pm
Evolus Third Quarter 2024 Earnings: Misses Expectations
- Nov 8th, 2024 11:10 am
Evolus Inc (EOLS) Q3 2024 Earnings Call Highlights: Revenue Surge Amid Market Challenges
- Nov 7th, 2024 11:00 am
Evolus, Inc. (EOLS) Reports Q3 Loss, Misses Revenue Estimates
- Nov 6th, 2024 11:25 pm
Evolus Reports Third Quarter 2024 Results
- Nov 6th, 2024 9:05 pm
Evolus to Participate in Stifel 2024 Healthcare Conference
- Nov 1st, 2024 12:00 pm
Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation
- Oct 31st, 2024 6:02 pm
Insulet (PODD) Earnings Expected to Grow: Should You Buy?
- Oct 31st, 2024 2:02 pm
Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know
- Oct 30th, 2024 2:01 pm
Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers
- Oct 29th, 2024 12:00 pm
Evolus to Report Third Quarter Financial Results on November 6, 2024
- Oct 23rd, 2024 12:00 pm
Evolus' (NASDAQ:EOLS) investors will be pleased with their solid 119% return over the last three years
- Oct 10th, 2024 3:29 pm
Evolus Inc (EOLS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements
- Oct 9th, 2024 7:36 pm
Scroll